肌缩侧面硬化症发病和进展的动力学
Michael Swash1,2, Mamede de Carvalho2,3
1Barts and the London School of Medicine, Queen Mary University of London, London E1 4NS, UK.
Brain sciences
|June 26, 2025
概括
肌缩性侧面硬化症 (ALS) 的发病复杂,具有漫长的临床前阶段,在运动神经元死亡之前涉及TDP-43蛋白质的积累. 早期发现和理解这些机制对于有效的治疗干预至关重要.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 肌缩性侧面硬化 (ALS) 呈现出渐进的肌肉衰弱,反映出较低的运动神经元过度兴奋.
- 疾病的发病包括一个长期的临床前阶段,标志着TDP-43蛋白质病变.
- 从明显的ALS症状区分早期的致病事件仍然是一个重大挑战.
研究的目的:
- 为了回顾肌缩性侧面硬化 (ALS) 发病的复杂性.
- 突出 ALS 的确切起源和早期致病机制的定义所面临的挑战.
- 强调了解TDP-43沉积和神经元退化对于治疗开发的重要性.
主要方法:
- 对有关ALS病原和临床表现的现有文献的审查.
- 对临床前阶段的分析,重点关注TDP-43的积累.
- 讨论上部和下部运动神经元参与和遗传突变.
主要成果:
- 病发性ALS是阴险的,其特征是TDP-43积累的长期临床前阶段.
- 从临床前转变为明显的ALS很难检测,影响早期治疗.
- 上部和下部运动神经元系统都参与ALS的进展.
结论:
- 了解TDP-43沉积和神经元退化的独特过程对于开发有效的ALS治疗非常重要.
- 对具有遗传突变的症状前患者进行跟踪对于研究很重要.
- 对ALS的早期发现和干预策略需要进一步调查.
相关概念视频
Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722
Cross-bridge Cycle
118.3K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
118.3K
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Long-term Potentiation
55.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K


